This is a working overview of N-acetyl Semax, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-24. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
As a result of its weak intrinsic androgenicity, CPA may not be as effective in the treatment of certain androgen-sensitive conditions such as prostate cancer compared to nonsteroidal antiandrogens with a silent antagonist profile at the AR. Indeed, CPA has never been found to extend life in prostate cancer patients when added to castration relative to castration alone, unlike nonsteroidal antiandrogens. As such, it is thought that the partial androgenic activity of CPA and other steroidal antiandrogens underlies the superior antiandrogenic efficacy of silent-antagonist nonsteroidal antiandrogens like flutamide. However, the clinical significance of the weak androgenic activity of CPA has also been disputed. In fact, some studies have found little or no stimulating effect of CPA on the prostate gland or seminal vesicles of male rats even with very high circulating concentrations of CPA. Nonsteroidal antiandrogens like flutamide and bicalutamide are more efficacious as antiandrogens than CPA in castrated animals due to their superior AR antagonistic activity. Conversely, CPA is a much more potent antiandrogen than nonsteroidal antiandrogens like flutamide and bicalutamide in gonadally intact male animals, which is due to its antigonadotropic effects and consequent suppression of testosterone levels (nonsteroidal antiandrogens do not suppress testosterone levels). CPA at high doses (e.g., 25–50 mg/day) has been reported to suppress SHBG levels, and may have a partial androgenic effect on hepatic SHBG production at such doses.
=== October === 9 October Críostóir Ó Floinn, 95, writer. Hugh Friel, 71, drummer (The Atrix). 10 October – Dónal O'Neill, 56, Gaelic footballer (Edenderry, Offaly senior team). 13 October – Hugh Russell, 63, boxer, Olympic bronze medallist (1980). 15 October – Gerry Ryan, 68, footballer (Bohemians, Derby County, Brighton, national team). 17 October – Paul Reynolds, 50, cricket umpire. 29 October – Jimmy Duggan, 93, hurler (Liam Mellows, Galway senior team, Connacht). 31 October – Séamus Leydon, 81, Gaelic footballer (Dunmore MacHales, Nemo Rangers, Galway senior team, Connacht).
== A == Acetylcholine A neurotransmitter involved in muscle activation, attention, arousal, and memory. It acts at both nicotinic and muscarinic receptors throughout the central and peripheral nervous systems. Achromatopsia Loss of color vision as a result of damage to extrastriate visual cortex. Action Potential A rapid electrical signal that travels down the axon of a neuron. Activation The time-dependent opening of ion channels in response to a stimulus, typically membrane depolarization. Adaptation The phenomenon of sensory receptor adjustment to different levels of stimulation; critical for allowing sensory systems to operate over a wide dynamic range. Adenylyl cyclase Membrane-bound enzyme that can be activated by G-proteins to catalyze the synthesis of cyclic AMP from ATP. Adrenal cortex The outer region of the adrenal gland, responsible for producing steroid hormones such as cortisol and aldosterone, which regulate metabolism and stress responses. Adrenal medulla The central part of the adrenal gland that, under visceral motor stimulation, secretes epinephrine and norepinephrine into the bloodstream. Adrenaline See epinephrine. Afferent nerve fiber An axon that conducts action potentials from the periphery toward the central nervous system. Agnosia The inability to name objects, typically resulting from brain damage in the occipital or temporal lobes. Agonist A chemical that binds to and activates a receptor, mimicking the action of a natural neurotransmitter.
Simon and Schuster. ISBN 978-1-4262-2005-0. Archived from the original on January 8, 2023. Retrieved January 8, 2023. Gainor, Chris (2001). Arrows to the Moon: Avro's Engineers and the Space Race. Burlington, Ontario: Apogee Books. ISBN 1-896522-83-1. Archived from the original on July 23, 2008. Retrieved August 2, 2019. Gatland, Kenneth (1976). Manned Spacecraft, Second Revision. New York: Macmillan Publishing Co., Inc. ISBN 0-02-542820-9. Hall, Rex; Shayler, David J. (2001). The Rocket Men: Vostok & Voskhod, The First Soviet Manned Spaceflights. New York: Springer–Praxis Books. ISBN 1-85233-391-X. Hall, Rex; Shayler, David J. (2003). Soyuz: A Universal Spacecraft. New York: Springer–Praxis Books. ISBN 1-85233-657-9. Hardesty, Von; Eisman, Gene (2007). Epic Rivalry: The Inside Story of the Soviet and American Space Race. Foreword by Sergei Khrushchev. Washington: National Geographic Society. ISBN 978-1-4262-0119-6. Harford, James J. (1997). Korolev: How One Man Masterminded the Soviet Drive to Beat America to the Moon (1 ed.). New York: John Wiley & Sons. ISBN 0-471-14853-9. Hepplewhite, T.A. (1999). The Space Shuttle Decision: NASA's Search for a Reusable Space Vehicle. Washington, DC: NASA. Jones, Eric M. (January 1, 2010). "Apollo 11 Lunar Surface Journal". Apollo Lunar Surface Journal. Internet. Archived from the original on January 16, 2012. Retrieved August 15, 2010. Kraft, Christopher C. (2001). Flight: My Life in Mission Control. New York: Dutton. ISBN 0-525-94571-7. Murray, Charles; Cox, Catherine Bly (1990). Apollo: The Race to the Moon.
A honey bee that is away from the hive foraging for nectar or pollen will rarely sting, except when stepped on or roughly handled. Honey bees will actively seek out and sting when they perceive the hive to be threatened, often being alerted to this by the release of attack pheromones (below). Although it is widely believed that a worker honey bee can sting only once, this is only partially true: although the stinger is in fact barbed so that it lodges in the victim's skin, tearing loose from the bee's abdomen and leading to its death in minutes, this only happens if the skin of the victim is sufficiently thick, such as a mammal's. Honey bees are the only hymenoptera with a strongly barbed sting, though yellow jackets and some other wasps have small barbs. The venom of the honeybee contains histamine, mast cell degranulating peptide, melittin, phospholipase A2, hyaluronidase and acid phosphatase. The three proteins in honeybee venom that are important allergens are phospholipase A2, hyaluronidase and acid phosphatase. In addition, the polypeptide melittin is also antigenic. Bumblebee venom appears to be chemically and antigenically related to honeybee venom. Bees with barbed stingers can often sting other insects without harming themselves. Queen honeybees and bees of many other species, including bumblebees and many solitary bees, have smoother stingers with smaller barbs and can sting mammals repeatedly. The sting's injection of apitoxin into the victim is accompanied by the release of alarm pheromones, a process which is accelerated if the bee is fatally injured.
Sources: en.wikipedia.org
During the beginning (acute) phase of inflammation, particularly as a result of bacterial infection, environmental exposure, and some cancers, neutrophils are one of the first responders of inflammatory cells to migrate toward the site of inflammation. They migrate through the blood vessels and then through interstitial space, following chemical signals such as interleukin-8 (IL-8), C5a, fMLP, leukotriene B4, and hydrogen peroxide (H2O2) in a process called chemotaxis. They are the predominant cells in pus, accounting for its whitish-to-yellowish appearance. Neutrophils are recruited to the site of injury within minutes following trauma and are the hallmark of acute inflammation. They not only play a central role in combating infection but also contribute to pain in the acute period by releasing pro-inflammatory cytokines and other mediators that sensitize nociceptors, leading to heightened pain perception. However, due to some pathogens being indigestible, they may not be able to resolve certain infections without the assistance of other types of immune cells.
Cells comprising the central nervous system and peripheral nervous system are classified as nervous (or neural) tissue. In the central nervous system, neural tissues form the brain and spinal cord. In the peripheral nervous system, neural tissues form the cranial nerves and spinal nerves, inclusive of the motor neurons.
Brenda Cecilia Agüero (born 2 June 1995) is an Argentine serial killer and former neonatal nurse convicted of the murder of five babies under her care. Between March and June 2022, Agüero deliberately injected healthy babies with overdoses of potassium or insulin (or both), killing five and causing decompensations in eight others. Agüero was charged with five counts of "aggravated murder for applying the insidious method of potassium incompatible with life". Agüero was later charged with eight other counts of attempted murder. The trial against Agüero and 10 provincial officials began on 6 January 2025. On 18 June 2025, Agüero was found guilty of all charges and sentenced to life in prison.
The Conservative Party under the leadership of Margaret Thatcher won the 1979 general election, placing the Labour Party back in opposition, which served to push the Liberals back into the margins. In 1981, defectors from a moderate faction of the Labour Party, led by former Cabinet ministers Roy Jenkins, David Owen, Shirley Williams and Bill Rodgers founded the Social Democratic Party (SDP). The new party and the Liberals quickly formed the SDP–Liberal Alliance, which for a while polled as high as 50% in the opinion polls and appeared capable of winning the next general election. Indeed, Steel was so confident of an Alliance victory that he told the 1981 Liberal conference, "Go back to your constituencies, and prepare for government!". However, the Alliance was overtaken in the polls by the Tories in the aftermath of the Falkland Islands War and at the 1983 general election the Conservatives were re-elected by a landslide, with Labour once again forming the opposition. While the SDP–Liberal Alliance came close to Labour in terms of votes (a share of more than 25%), it only had 23 MPs compared to Labour's 209. The Alliance's support was spread out across the country, and was not concentrated in enough areas to translate into seats. In the 1987 general election, the Alliance's share of the votes fell slightly and it now had 22 MPs. In the election's aftermath Steel proposed a merger of the two parties. Most SDP members voted in favour of the merger, but SDP leader David Owen objected and continued to lead a "rump" SDP.
=== Selenoproteins === Selenocysteine has a lower reduction potential than cysteine. These properties make it very suitable in proteins that are involved in antioxidant activity. Although it is found in the three domains of life, it is not universal in all organisms. Unlike other amino acids present in biological proteins, selenocysteine is not coded for directly in the genetic code. Instead, it is encoded in a special way by a UGA codon, which is normally the "opal" stop codon. Such a mechanism is called translational recoding and its efficiency depends on the selenoprotein being synthesized and on translation initiation factors. When cells are grown in the absence of selenium, translation of selenoproteins terminates at the UGA codon, resulting in a truncated, nonfunctional enzyme. The UGA codon is made to encode selenocysteine by the presence of a selenocysteine insertion sequence (SECIS) in the mRNA. The SECIS element is defined by characteristic nucleotide sequences and secondary structure base-pairing patterns. In bacteria, the SECIS element is typically located immediately following the UGA codon within the reading frame for the selenoprotein. In Archaea and in eukaryotes, the SECIS element is in the 3′ untranslated region (3′ UTR) of the mRNA and can direct multiple UGA codons to encode selenocysteine residues. As of 2021, 136 human proteins (in 37 families) are known to contain selenocysteine (selenoproteins).
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.